New Device Significantly Simplifies the Treatment of Abdominal Aortic Aneurysms
IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX) today announced the full commercial launch of the InutiTrak(TM) Express Delivery System for the endovascular treatment of large neck abdominal aortic aneurysms (AAA). The IntuiTrak family of devices features low profile, minimally invasive endovascular delivery systems that enhance vascular accessibility and maneuverability while simplifying the deployment of the Company's Powerlink stent graft products. As the newest addition to the IntuiTrak platform, IntuiTrak Express incorporates novel design and deployment features that enable the delivery of the Powerlink XL stent graft through the IntuiTrak 19Fr introducer sheath. This is the lowest profile delivery system currently available in the US for the endovascular repair of AAA in patients with aortic necks up to 32mm in diameter.
John McDermott, President and CEO of Endologix, said, "IntuiTrak Express expands our portfolio into a comprehensive suite of products that address a broad range of patient anatomies and physician preferences. Most importantly, it allows physicians to easily deliver and deploy our Powerlink XL stent graft through a single 19Fr introducer sheath, which has demonstrated the potential to reduce procedure times while minimizing blood loss and vessel trauma. We believe this will allow us to gain a greater share of physicians' AAA procedures based upon the ease of use and strong clinical outcomes achieved in patients with large aortic necks and other AAA anatomies. Early physician feedback on IntuiTrak Express was very positive during its limited release, so we accelerated the full commercial launch ahead of our original guidance to launch in the third quarter of this year."
The IntuiTrak Express Delivery System will be featured from June 11-14, 2009 at the Annual Meeting of the Society for Vascular Surgery (SVS) in Denver, Colorado. The Company's complete product portfolio will also be on display at the SVS meeting in the Company's booth #625.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink(R) System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
Except for historical information contained herein, this news release contains forward-looking statements, specifically with respect to the full commercialization of the IntuiTrak Express Delivery System for the Powerlink XL, accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the success of sales efforts for the Powerlink System and related new products, product research and development efforts, and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
COMPANY CONTACT: INVESTOR CONTACTS: ---------------- ------------------ Endologix, Inc. The Ruth Group John McDermott, CEO Nick Laudico (646) 536-7030 (949) 595-7200 Zack Kubow (646) 536-7020 www.endologix.com
|SOURCE Endologix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved